Patrick Roth
A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol.
Mastall M, Roth P, Bink A, Maranta A, Läubli H, Hottinger A, Hundsberger T, Migliorini D, Ochsenbein A, Seystahl K, Imbach L, Hortobágyi T, Held L, Weller M, Wirsching H. A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol. BMC cancer 2024; 24:82.
Jan 15, 2024A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol.
Jan 15, 2024BMC cancer 2024; 24:82
Mastall Maximilian, Roth Patrick, Bink Andrea, Maranta Angela Fischer, Läubli Heinz, Hottinger Andreas Felix, Hundsberger Thomas, Migliorini Denis, Ochsenbein Adrian F, Seystahl Katharina, Imbach Lukas L, Hortobágyi Tibor, Held Leonhard, Weller Michael, Wirsching Hans-Georg
Glioblastoma in the oldest old: Clinical characteristics, therapy, and outcome in patients aged 80 years and older.
Stadler C, Gramatzki D, Le Rhun E, Hottinger A, Hundsberger T, Roelcke U, Läubli H, Hofer S, Seystahl K, Wirsching H, Weller M, Roth P. Glioblastoma in the oldest old: Clinical characteristics, therapy, and outcome in patients aged 80 years and older. Neurooncol Pract 2023; 11:132-141.
Oct 20, 2023Glioblastoma in the oldest old: Clinical characteristics, therapy, and outcome in patients aged 80 years and older.
Oct 20, 2023Neurooncol Pract 2023; 11:132-141
Stadler Christina, Gramatzki Dorothee, Le Rhun Emilie, Hottinger Andreas Felix, Hundsberger Thomas, Roelcke Ulrich, Läubli Heinz, Hofer Silvia, Seystahl Katharina, Wirsching Hans-Georg, Weller Michael, Roth Patrick
Immune checkpoint inhibitors induced side effects of the peripheral nervous system.
Hundsberger T, Schreiner B, Roth P. Immune checkpoint inhibitors induced side effects of the peripheral nervous system. Curr Opin Neurol 2023; 36:427-431.
Jul 24, 2023Immune checkpoint inhibitors induced side effects of the peripheral nervous system.
Jul 24, 2023Curr Opin Neurol 2023; 36:427-431
Hundsberger Thomas, Schreiner Bettina, Roth Patrick
A T-cell antigen atlas for meningioma: novel options for immunotherapy.
Medici G, Freudenmann L, Velz J, Wang S, Kapolou K, Paramasivam N, Mühlenbruch L, Kowalewski D, Vasella F, Bilich T, Frey B, Dubbelaar M, Patterson A, Zeitlberger A, Silginer M, Roth P, Weiss T, Wirsching H, Krayenbühl N, Bozinov O, Regli L, Rammensee H, Rushing E, Sahm F, Walz J, Weller M, Neidert M. A T-cell antigen atlas for meningioma: novel options for immunotherapy. Acta Neuropathol 2023; 146:173-190.
Jun 27, 2023A T-cell antigen atlas for meningioma: novel options for immunotherapy.
Jun 27, 2023Acta Neuropathol 2023; 146:173-190
Medici Gioele, Freudenmann Lena Katharina, Velz Julia, Wang Sophie Shih-Yüng, Kapolou Konstantina, Paramasivam Nagarajan, Mühlenbruch Lena, Kowalewski Daniel Johannes, Vasella Flavio, Bilich Tatjana, Frey Beat M, Dubbelaar MariLisa, Patterson Angelica Brooke, Zeitlberger Anna Maria, Silginer Manuela, Roth Patrick, Weiss Tobias, Wirsching Hans-Georg, Krayenbühl Niklaus, Bozinov Oliver, Regli Luca, Rammensee Hans-Georg, Rushing Elisabeth Jane, Sahm Felix, Walz Juliane Sarah, Weller Michael, Neidert Marian Christoph
Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study.
Jörger M, Hundsberger T, Haefliger S, von Moos R, Hottinger A, Kaindl T, Engelhardt M, Marszewska M, Lane H, Roth P, Stathis A. Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study. Invest New Drugs 2023; 41:267-275.
Feb 16, 2023Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study.
Feb 16, 2023Invest New Drugs 2023; 41:267-275
Jörger Markus, Hundsberger Thomas, Haefliger Simon, von Moos Roger, Hottinger Andreas F, Kaindl Thomas, Engelhardt Marc, Marszewska Michalina, Lane Heidi, Roth Patrick, Stathis Anastasios
Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma.
Wang J, Weiss T, Neidert M, Toussaint N, Naghavian R, Sellés Moreno C, Foege M, Tomas Ojer P, Medici G, Jelcic I, Schulz D, Rushing E, Dettwiler S, Schrörs B, Shin J, McKay R, Wu C, Lutterotti A, Sospedra M, Moch H, Greiner E, Bodenmiller B, Regli L, Weller M, Roth P, Martin R. Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma. Clin Cancer Res 2022; 28:5368-5382.
Dec 15, 2022Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma.
Dec 15, 2022Clin Cancer Res 2022; 28:5368-5382
Wang Jian, Weiss Tobias, Neidert Marian C, Toussaint Nora C, Naghavian Reza, Sellés Moreno Carla, Foege Magdalena, Tomas Ojer Paula, Medici Gioele, Jelcic Ivan, Schulz Daniel, Rushing Elisabeth, Dettwiler Susanne, Schrörs Barbara, Shin Joo Heon, McKay Ron, Wu Catherine J, Lutterotti Andreas, Sospedra Mireia, Moch Holger, Greiner Erich F, Bodenmiller Bernd, Regli Luca, Weller Michael, Roth Patrick, Martin Roland
Fitness-to-drive for glioblastoma patients: Guidance from the Swiss Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM)
Hofer S, Baumert B, Läubli H, Gramatzki D, Reinert M, Pesce G, Schucht P, Frank I, Lehnick D, Weiss T, Wirsching H, Wolpert F, Roth P, Eggenberger N, Pflugshaupt T, Keller K, Imbach L, Roelcke U, Hutter G, Hundsberger T, Hertler C, Le Rhun E, Vasella F, Cordier D, Neidert M, Hottinger A, Migliorini D, Weller M. Fitness-to-drive for glioblastoma patients: Guidance from the Swiss Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM). Swiss Med Wkly 2021; 151:w20501.
May 16, 2021Fitness-to-drive for glioblastoma patients: Guidance from the Swiss Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM)
May 16, 2021Swiss Med Wkly 2021; 151:w20501
Hofer Silvia, Baumert Brigitta, Läubli Heinz, Gramatzki Dorothee, Reinert Michael, Pesce Gianfranco, Schucht Philippe, Frank Irène, Lehnick Dirk, Weiss Tobias, Wirsching Hans-Georg, Wolpert Fabian, Roth Patrick, Eggenberger Noemi, Pflugshaupt Tobias, Keller Kristina, Imbach Lukas, Roelcke Ulrich, Hutter Gregor, Hundsberger Thomas, Hertler Caroline, Le Rhun Emilie, Vasella Flavio, Cordier Dominik, Neidert Marian Christoph, Hottinger Andreas, Migliorini Denis, Weller Michael
MRI and FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial
Wirsching H, Tabatabai G, Ochsenbein A, Roth P, Remonda L, Conen K, Caparrotti F, von Moos R, Hottinger A, Hundsberger T, Weller J, Roelcke U, Weller M. MRI and FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial. Clin Cancer Res 2020; 27:179-188.
Sep 23, 2020MRI and FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial
Sep 23, 2020Clin Cancer Res 2020; 27:179-188
Wirsching Hans-Georg, Tabatabai Ghazaleh, Ochsenbein Adrian, Roth Patrick, Remonda Luca, Conen Katrin, Caparrotti Francesca, von Moos Roger, Hottinger Andreas F, Hundsberger Thomas, Weller Jonathan, Roelcke Ulrich, Weller Michael
A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults
Roth P, Hofer S, Pesce G, Roelcke U, Mamot C, Reinert M, Schucht P, Läubli H, Hundsberger T, Hottinger A, Weller M. A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults. Swiss Med Wkly 2020; 150:w20256.
Jun 18, 2020A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults
Jun 18, 2020Swiss Med Wkly 2020; 150:w20256
Roth Patrick, Hofer Silvia, Pesce Gianfranco, Roelcke Ulrich, Mamot Christoph, Reinert Michael, Schucht Philippe, Läubli Heinz, Hundsberger Thomas, Hottinger Andreas F, Weller Michael
Venous thromboembolic events in patients with brain metastases: the PICOS score
Wolpert F, Preusser M, Le Rhun E, Andratschke N, Neidert M, Roth P, Löb R, Lareida A, Grossenbacher B, Berghoff A, Weller M. Venous thromboembolic events in patients with brain metastases: the PICOS score. Eur J Cancer 2020; 134:75-85.
May 27, 2020Venous thromboembolic events in patients with brain metastases: the PICOS score
May 27, 2020Eur J Cancer 2020; 134:75-85
Wolpert Fabian, Preusser Matthias, Le Rhun Emilie, Andratschke Nicolaus, Neidert Marian Christoph, Roth Patrick, Löb Raphael, Lareida Anna, Grossenbacher Bettina, Berghoff Anna S, Weller Michael
Antidepressant drug use in glioblastoma patients: an epidemiological view
Gramatzki D, Rogers J, Neidert M, Hertler C, Le Rhun E, Roth P, Weller M. Antidepressant drug use in glioblastoma patients: an epidemiological view. Neurooncol Pract 2020; 7:514-521.
Apr 25, 2020Antidepressant drug use in glioblastoma patients: an epidemiological view
Apr 25, 2020Neurooncol Pract 2020; 7:514-521
Gramatzki Dorothee, Rogers James Louis, Neidert Marian Christoph, Hertler Caroline, Le Rhun Emilie, Roth Patrick, Weller Michael
Risk factors for the development of epilepsy in patients with brain metastases
Wolpert F, Le Rhun E, Imbach L, Poryazova R, Roth P, Neidert M, Grossenbacher B, Terziev R, Lareida A, Weller M. Risk factors for the development of epilepsy in patients with brain metastases. Neuro Oncol 2020; 22:718-728.
Jan 15, 2020Risk factors for the development of epilepsy in patients with brain metastases
Jan 15, 2020Neuro Oncol 2020; 22:718-728
Wolpert Fabian, Le Rhun Emilie, Imbach Lukas L, Poryazova Rositsa, Roth Patrick, Neidert Marian Christoph, Grossenbacher Bettina, Terziev Robert, Lareida Anna, Weller Michael
High-throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification
Zhu Y, Christiansen A, Fritz C, Rupp N, Poyet C, Rushing E, Weller M, Roth P, Haralambieva E, Hofer S, Chen C, Jochum W, Gao X, Teng X, Chen L, Zhong Q, Wild P, Aebersold R, Ljubicic J, Rutishauser D, Schmid M, Weiss T, Zhang Q, Sun R, Wang B, Yi X, Wu Z, Gao H, Cai X, Ruan G, Zhu T, Xu C, Lou S, Yu X, Gillet L, Blattmann P, Saba K, Fankhauser C, Guo T. High-throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification. Mol Oncol 2019; 13:2305-2328.
Sep 18, 2019High-throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification
Sep 18, 2019Mol Oncol 2019; 13:2305-2328
Zhu Yi, Christiansen Ailsa, Fritz Christine, Rupp Niels J, Poyet Cédric, Rushing Elisabeth, Weller Michael, Roth Patrick, Haralambieva Eugenia, Hofer Silvia, Chen Chen, Jochum Wolfram, Gao Xiaofei, Teng Xiaodong, Chen Lirong, Zhong Qing, Wild Peter J, Aebersold Ruedi, Ljubicic Jelena, Rutishauser Dorothea, Schmid Michael, Weiss Tobias, Zhang Qiushi, Sun Rui, Wang Bo, Yi Xiao, Wu Zhicheng, Gao Huanhuan, Cai Xue, Ruan Guan, Zhu Tiansheng, Xu Chao, Lou Sai, Yu Xiaoyan, Gillet Ludovic, Blattmann Peter, Saba Karim, Fankhauser Christian D, Guo Tiannan
Diagnostic value of F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site
Wolpert F, Preusser M, Kaufmann P, Reyns N, Roth P, Frauenfelder T, Dummer R, Stahel R, Stupp R, Neidert M, Regli L, Andratschke N, Leske H, Petyt G, Füreder L, Rushing E, Berghoff A, Weller M, Le Rhun E. Diagnostic value of F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site. Eur J Cancer 2018; 96:64-72.
Apr 17, 2018Diagnostic value of F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site
Apr 17, 2018Eur J Cancer 2018; 96:64-72
Wolpert Fabian, Preusser Matthias, Kaufmann Philipp Antonio, Reyns Nicolas, Roth Patrick, Frauenfelder Thomas, Dummer Reinhard, Stahel Rolf, Stupp Roger, Neidert Marian Christoph, Regli Luca, Andratschke Nicolaus, Leske Henning, Petyt Gregory, Füreder Lisa Michaela, Rushing Elisabeth, Berghoff Anna Sophie, Weller Michael, Le Rhun Emilie
The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy
Neidert M, Rammensee H, Henschler R, Lamszus K, Westphal M, Roth P, Regli L, Stevanovic S, Weller M, Wolpert F, Walz J, Kowalewski D, Silginer M, Kapolou K, Backert L, Freudenmann L, Peper J, Marcu A, Wang S, Eisele G. The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy. Acta Neuropathol 2018; 135:923-938.
Mar 20, 2018The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy
Mar 20, 2018Acta Neuropathol 2018; 135:923-938
Neidert Marian Christoph, Rammensee Hans-Georg, Henschler Reinhard, Lamszus Katrin, Westphal Manfred, Roth Patrick, Regli Luca, Stevanovic Stefan, Weller Michael, Wolpert Fabian, Walz Juliane Sarah, Kowalewski Daniel Johannes, Silginer Manuela, Kapolou Konstantina, Backert Linus, Freudenmann Lena Katharina, Peper Janet Kerstin, Marcu Ana, Wang Sophie Shih-Yüng, Eisele Günter
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
Wick W, Golfinopoulos V, Frenel J, Campone M, Ricard D, Marosi C, Villa S, Weyerbrock A, Hopkins K, Homicsko K, Lhermitte B, Pesce G, Roth P, Stupp R, Gorlia T, Bady P, Platten M, van den Bent M, Taphoorn M, Steuve J, Brandes A, Hamou M, Wick A, Kosch M, Weller M, Hegi M. Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082). Clin Cancer Res 2016; 22:4797-4806.
May 3, 2016Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
May 3, 2016Clin Cancer Res 2016; 22:4797-4806
Wick Wolfgang, Golfinopoulos Vassilis, Frenel Jean-Sebastien, Campone Mario, Ricard Damien, Marosi Christine, Villa Salvador, Weyerbrock Astrid, Hopkins Kirsten, Homicsko Krisztian, Lhermitte Benoit, Pesce Gianfranco, Roth Patrick, Stupp Roger, Gorlia Thierry, Bady Pierre, Platten Michael, van den Bent Martin J, Taphoorn Martin J B, Steuve Jonathan, Brandes Alba A, Hamou Marie-France, Wick Antje, Kosch Markus, Weller Michael, Hegi Monika E
Interferon-β Modulates the Innate Immune Response against Glioblastoma Initiating Cells
Wolpert F, Weller M, Westphal M, Lamszus K, Neidert M, Roth P, Deenen R, Florea A, Reifenberger G, Happold C, Eisele G. Interferon-β Modulates the Innate Immune Response against Glioblastoma Initiating Cells. PloS one 2015; 10:e0139603.
Oct 6, 2015Interferon-β Modulates the Innate Immune Response against Glioblastoma Initiating Cells
Oct 6, 2015PloS one 2015; 10:e0139603
Wolpert Fabian, Weller Michael, Westphal Manfred, Lamszus Katrin, Neidert Marian Christoph, Roth Patrick, Deenen René, Florea Ana-Maria, Reifenberger Guido, Happold Caroline, Eisele Günter
Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma
Korfel A, Junghanß C, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Roth P, Bamberg M, Pietsch T, Mergenthaler H, Hundsberger T, Thiel E, Martus P, Möhle R, Griesinger F, Rauch M, Röth A, Hertenstein B, Fischer T, Weller M. Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. Neurology 2015; 84:1242-8.
Feb 25, 2015Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma
Feb 25, 2015Neurology 2015; 84:1242-8
Korfel Agnieszka, Junghanß Christian, Birnbaum Tobias, Fischer Lars, Jahnke Kristoph, Herrlinger Ulrich, Roth Patrick, Bamberg Michael, Pietsch Torsten, Mergenthaler Hans G, Hundsberger Thomas, Thiel Eckhard, Martus Peter, Möhle Robert, Griesinger Frank, Rauch Michael, Röth Alexander, Hertenstein Bernd, Fischer Thomas, Weller Michael
Neurologische Komplikationen bei onkologischen Patienten
Hundsberger T, Roth P, Roelke U. Neurologische Komplikationen bei onkologischen Patienten. Praxis 2014 2014; 103:1009-1016.
Aug 25, 2014Neurologische Komplikationen bei onkologischen Patienten
Aug 25, 2014Praxis 2014 2014; 103:1009-1016
Hundsberger Thomas, Roth Patrick, Roelke Ulrich
[Neurological complications in cancer patients]
Hundsberger T, Roth P, Roelcke U. [Neurological complications in cancer patients]. Praxis (Bern 1994) 2014; 103:1009-16.
Aug 20, 2014[Neurological complications in cancer patients]
Aug 20, 2014Praxis (Bern 1994) 2014; 103:1009-16
Hundsberger Thomas, Roth Patrick, Roelcke Ulrich